Product Description
Mechanisms of Action: 5-HT2A Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Sio Gene Therapies
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Dementia|Lewy Body Dementia|Insomnia|Alzheimer Disease|Hallucinations|Lewy Body Disease|Parkinson's Disease|REM Sleep Behavior Disorder
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| RVT-102-2003 | P2 |
Terminated |
REM Sleep Behavior Disorder|Alzheimer Disease|Parkinson's Disease|Hallucinations|Lewy Body Disease|Lewy Body Dementia |
2019-01-17 |
30% |
| DLB or PDD | P2 |
Completed |
Lewy Body Disease|REM Sleep Behavior Disorder|Alzheimer Disease|Parkinson's Disease|Lewy Body Dementia |
2018-05-01 |
|
| RVT-102-2001 | P2 |
Completed |
Lewy Body Dementia|Dementia|Lewy Body Disease|Hallucinations |
2017-11-01 |
|
| APD125-007 | P2 |
Completed |
Insomnia |
2008-10-01 |
31% |